HRP20210458T1 - Cjepivo za imunološki kompromitirane domaćine - Google Patents
Cjepivo za imunološki kompromitirane domaćine Download PDFInfo
- Publication number
- HRP20210458T1 HRP20210458T1 HRP20210458TT HRP20210458T HRP20210458T1 HR P20210458 T1 HRP20210458 T1 HR P20210458T1 HR P20210458T T HRP20210458T T HR P20210458TT HR P20210458 T HRP20210458 T HR P20210458T HR P20210458 T1 HRP20210458 T1 HR P20210458T1
- Authority
- HR
- Croatia
- Prior art keywords
- vaccine
- peptide
- sepsis
- bacteria
- antibody
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims 10
- 206010061598 Immunodeficiency Diseases 0.000 title claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 206010040047 Sepsis Diseases 0.000 claims 11
- 241000894006 Bacteria Species 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims 5
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 241000588650 Neisseria meningitidis Species 0.000 claims 3
- 241000589516 Pseudomonas Species 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 241000588724 Escherichia coli Species 0.000 claims 2
- 206010017964 Gastrointestinal infection Diseases 0.000 claims 2
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 208000005107 Premature Birth Diseases 0.000 claims 2
- 206010062255 Soft tissue infection Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 208000037815 bloodstream infection Diseases 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 206010014665 endocarditis Diseases 0.000 claims 2
- 208000010227 enterocolitis Diseases 0.000 claims 2
- 102000047486 human GAPDH Human genes 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000002254 stillbirth Diseases 0.000 claims 2
- 231100000537 stillbirth Toxicity 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 208000019206 urinary tract infection Diseases 0.000 claims 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 210000000628 antibody-producing cell Anatomy 0.000 claims 1
- 230000001010 compromised effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 210000003754 fetus Anatomy 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0266—Klebsiella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
- C12Y102/01012—Glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) (1.2.1.12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
- C12Y102/01022—Lactaldehyde dehydrogenase (1.2.1.22)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Claims (17)
1. Izolirani peptid koji ima najmanje 90% identičnosti sekvence aminokiseline s bilo kojom od SEQ ID NO: 9-69, naznačen time što je peptid duljine najmanje 8 aminokiselina i manje od 50 aminokiselina, te je sposoban izazvati antitijela koja vežu i neutraliziraju GAPDH skupine B streptokoka (GBS) E. coli, Staphilococcus spp., S. pneumoniae, K. pneumoniae, N. meningitidis ili Pseudomonas spp., ali ne vežu ljudski GAPDH.
2. Izolirani peptid prema patentnom zahtjevu 1, naznačen time što izolirani peptid ima aminokiselinsku sekvencu kako je navedeno u bilo kojoj od SEQ ID NO: 9-69.
3. Izolirani peptid prema bilo kojem od patentnih zahtjeva 1 do 2, naznačen time što je izolirani peptid konjugiran na protein nosač.
4. Izolirana nukleinska kiselina naznačena time što kodira peptid prema bilo kojem od patentnih zahtjeva 1 do 2.
5. Upotreba peptida prema bilo kojem od patentnih zahtjeva 1 do 3, u razvoju cjepiva za sprečavanje infekcije bakterijama koje izazivaju sepsu.
6. Cjepivo naznačeno time što sadrži peptid prema bilo kojem od patentnih zahtjeva 1 do 3.
7. Cjepivo prema patentnom zahtjevu 6, koje sadrži:
a) dva ili više peptida prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu su najmanje dva peptida povezana zajedno; i/ili
b) bilo koji jedan, dva, tri ili sva četiri peptida koji imaju aminokiselinske sekvence kako je navedeno u SEQ ID NO: 9-12.
8. Cjepivo prema patentnom zahtjevu 6 ili zahtjevu 7, naznačeno time što je formulirano za za primjenu imunološki kompromitiranom domaćinu.
9. Cjepivo prema patentnom zahtjevu 8, naznačeno time što je imunološki kompromitirani domaćin odabran od novorođenčeta, djeteta, djeteta, žene plodne dobi, trudnice, fetusa, dijabetičara i/ili starijeg subjekta.
10. Upotreba in vitro ili ex vivo peptida prema bilo kojem od patentnih zahtjeva 1 do 3, ili cjepiva prema bilo kojem od patentnih zahtjeva 6 do 9, za poticanje imunološkog odgovora.
11. Uporaba prema patentnom zahtjevu 10, naznačena time što imunološki odgovor obuhvaća proizvodnju antitijela koja su specifična za GAPDH jedne ili više vrsta bakterija koje izazivaju sepsu i/ili uporaba je za poticanje proizvodnje monoklonskih ili poliklonskih protutijela.
12. Peptid prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što se koristi u terapiji.
13. Peptid prema bilo kojem od patentnih zahtjeva 1 do 3, ili cjepivo prema bilo kojem od patentnih zahtjeva 6 do 9, naznačeno time što se koristi za sprečavanje:
a) infekcija bakterijama koje uzrokuju sepsu; i/ili
b) bilo kojeg ili više od sepse, upale pluća, meningitisa, endokarditisa, enterokolitisa, infekcija mokraćnog sustava, infekcija mekih tkiva, gastrointestinalnih infekcija, infekcija krvotoka, encefalitisa, prijevremenih poroda i mrtvorođenih.
14. Protutijelo koje je specifično za epitop pronađen u GAPDH jedne ili više vrsta bakterija koje izazivaju sepsu, pri čemu se navedeno protutijelo podiže protiv peptida prema bilo kojem od patentnih zahtjeva 1 do 3 ili cjepiva prema bilo kojem od patentnih zahtjeva 6 do 9 i pri čemu protutijelo veže i neutralizira GAPDH od GBS, E coli, Staphilococcus spp, S. pneumoniae, K. pneumoniae, N. meningitidis ili Pseudomonas spp, ali ne veže ljudski GAPDH.
15. Protutijelo prema patentnom zahtjevu 14, naznačeno time što se koristi za:
a) terapiju;
b) sprečavanje, liječenje ili ublažavanje infekcije bakterijama koje uzrokuju sepsu; i/ili
c) sprečavanje, liječenje ili poboljšanje bilo kojeg ili više od sepse, upale pluća, meningitisa, endokarditisa, enterokolitisa, infekcija mokraćnog sustava, infekcija mekih tkiva, gastrointestinalnih infekcija, infekcija krvotoka i encefalitisa, i/ili za uporabu u sprečavanju prijevremenih poroda i/ili mrtvorođenčadi.
16. Postupak za proizvodnju protutijela koja su specifična za GAPDH jedne ili više vrsta bakterija koje izazivaju sepsu, te postupak obuhvaća korak dovođenja u kontakt stanica koje proizvode protutijela s peptidom prema bilo kojem od patentnih zahtjeva 1 do 3, ili cjepiva prema bilo kojem od patentnih zahtjeva 6 do 9, naznačeno time što je postupak:
a) in vitro ili ex vivo postupak za proizvodnju monoklonskih ili poliklonskih protutijela; ili
b) in vivo postupak neterapijskog cijepljenja subjekta koji nije čovjek.
17. Uporaba prema patentnom zahtjevu 5 ili zahtjevu 11, peptide za uporabu prema patentnom zahtjevu 13, postupak prema patentnom zahtjevu 16, protutijelo prema patentnom zahtjevu 14, ili protutijelo za uporabu prema patentnom zahtjevu 15, naznačena time što su bakterije koje izazivaju sepsu odabrane iz skupine koju čine GBS, E. coli, Staphilococcus spp., S. pneumoniae, K. pneumoniae, Pseudomonas spp. i N. meningitidis.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14398006.8A EP2955194A1 (en) | 2014-06-12 | 2014-06-12 | Neonatal vaccine |
| EP15398003 | 2015-03-30 | ||
| EP15728546.1A EP3155004B1 (en) | 2014-06-12 | 2015-06-12 | Vaccine for immunocompromised hosts |
| PCT/EP2015/063243 WO2015189422A1 (en) | 2014-06-12 | 2015-06-12 | Vaccine for immunocompromised hosts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210458T1 true HRP20210458T1 (hr) | 2021-05-14 |
Family
ID=53385660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210458TT HRP20210458T1 (hr) | 2014-06-12 | 2021-03-18 | Cjepivo za imunološki kompromitirane domaćine |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11066652B2 (hr) |
| EP (1) | EP3155004B1 (hr) |
| JP (2) | JP6813480B2 (hr) |
| KR (2) | KR20170018920A (hr) |
| CN (1) | CN106795502B (hr) |
| CA (1) | CA2969878C (hr) |
| CY (1) | CY1124388T1 (hr) |
| DK (1) | DK3155004T3 (hr) |
| ES (1) | ES2862534T3 (hr) |
| HR (1) | HRP20210458T1 (hr) |
| HU (1) | HUE053668T2 (hr) |
| LT (1) | LT3155004T (hr) |
| MA (1) | MA39957B1 (hr) |
| PL (1) | PL3155004T3 (hr) |
| RS (1) | RS61549B1 (hr) |
| SI (1) | SI3155004T1 (hr) |
| WO (1) | WO2015189422A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106795502B (zh) | 2014-06-12 | 2021-12-14 | 波尔图大学 | 用于免疫受损宿主的疫苗 |
| US11718648B2 (en) | 2017-01-05 | 2023-08-08 | Evaxion Biotech A/S | Vaccines targeting Pseudomonas aeruginosa |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ532894A (en) * | 1998-04-29 | 2005-10-28 | Univ Southern California | Retroviral vectors including modified envelope escort proteins |
| JP2008529504A (ja) * | 2005-02-08 | 2008-08-07 | ニューヨーク ブラッド センター | 重症急性呼吸器症候群関連コロナウイルスに対する中和モノクローナル抗体 |
| WO2007132461A2 (en) * | 2006-05-11 | 2007-11-22 | Ramot At Tel Aviv University Ltd. | Classification of protein sequences and uses of classified proteins |
| ES2298055A1 (es) * | 2006-08-09 | 2008-05-01 | Fundacion Marques De Valdecilla | Peptidos inmunogenicos frente a los generos listeria y mycobacterium, anticuerpos y usos de los mismos. |
| US20120100172A1 (en) * | 2009-06-25 | 2012-04-26 | Michael Tal | Immunogenic streptococcus pneumoniae peptides and peptide-multimers |
| JP2013503158A (ja) * | 2009-08-26 | 2013-01-31 | ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ | 炎症性サイトカインカスケードによって媒介される病態を、ｇａｐｄｈ阻害剤を用いて治療する方法 |
| WO2011067758A2 (en) * | 2009-12-02 | 2011-06-09 | Protea Vaccine Technologies Ltd. | Immunogenic fragments and multimers from streptococcus pneumoniae proteins |
| EP2550529B1 (en) * | 2010-03-23 | 2021-11-17 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| WO2014055897A2 (en) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| CN106795502B (zh) | 2014-06-12 | 2021-12-14 | 波尔图大学 | 用于免疫受损宿主的疫苗 |
-
2015
- 2015-06-12 CN CN201580031464.1A patent/CN106795502B/zh active Active
- 2015-06-12 EP EP15728546.1A patent/EP3155004B1/en active Active
- 2015-06-12 CA CA2969878A patent/CA2969878C/en active Active
- 2015-06-12 HU HUE15728546A patent/HUE053668T2/hu unknown
- 2015-06-12 JP JP2017517417A patent/JP6813480B2/ja active Active
- 2015-06-12 SI SI201531564T patent/SI3155004T1/sl unknown
- 2015-06-12 PL PL15728546T patent/PL3155004T3/pl unknown
- 2015-06-12 WO PCT/EP2015/063243 patent/WO2015189422A1/en active Application Filing
- 2015-06-12 US US15/313,327 patent/US11066652B2/en active Active
- 2015-06-12 MA MA39957A patent/MA39957B1/fr unknown
- 2015-06-12 LT LTEP15728546.1T patent/LT3155004T/lt unknown
- 2015-06-12 ES ES15728546T patent/ES2862534T3/es active Active
- 2015-06-12 KR KR1020177001052A patent/KR20170018920A/ko active Search and Examination
- 2015-06-12 KR KR1020207002884A patent/KR20200013809A/ko not_active Application Discontinuation
- 2015-06-12 DK DK15728546.1T patent/DK3155004T3/da active
- 2015-06-12 RS RS20210294A patent/RS61549B1/sr unknown
-
2020
- 2020-09-29 JP JP2020163456A patent/JP2021000134A/ja active Pending
-
2021
- 2021-03-18 HR HRP20210458TT patent/HRP20210458T1/hr unknown
- 2021-04-07 CY CY20211100298T patent/CY1124388T1/el unknown
- 2021-05-26 US US17/331,536 patent/US11834684B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN106795502A (zh) | 2017-05-31 |
| US11066652B2 (en) | 2021-07-20 |
| PL3155004T3 (pl) | 2021-10-25 |
| MA39957B1 (fr) | 2021-04-30 |
| ES2862534T3 (es) | 2021-10-07 |
| EP3155004A1 (en) | 2017-04-19 |
| DK3155004T3 (da) | 2021-04-06 |
| KR20170018920A (ko) | 2017-02-20 |
| US20220049229A1 (en) | 2022-02-17 |
| RS61549B1 (sr) | 2021-04-29 |
| CA2969878C (en) | 2021-05-04 |
| LT3155004T (lt) | 2021-03-25 |
| KR20200013809A (ko) | 2020-02-07 |
| CA2969878A1 (en) | 2015-12-17 |
| CN106795502B (zh) | 2021-12-14 |
| EP3155004B1 (en) | 2021-01-13 |
| MA39957A (fr) | 2017-04-19 |
| US20170191040A1 (en) | 2017-07-06 |
| JP2017518769A (ja) | 2017-07-13 |
| US11834684B2 (en) | 2023-12-05 |
| WO2015189422A1 (en) | 2015-12-17 |
| HUE053668T2 (hu) | 2021-07-28 |
| CY1124388T1 (el) | 2022-07-22 |
| JP2021000134A (ja) | 2021-01-07 |
| SI3155004T1 (sl) | 2021-08-31 |
| JP6813480B2 (ja) | 2021-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gauger et al. | Live attenuated influenza A virus vaccine protects against A (H1N1) pdm09 heterologous challenge without vaccine associated enhanced respiratory disease | |
| HRP20210096T1 (hr) | Novi oblik il33, mutirani oblici il33, protutijela, testovi i postupci njegove upotrebe | |
| RU2014101707A (ru) | АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ | |
| HRP20210458T1 (hr) | Cjepivo za imunološki kompromitirane domaćine | |
| Su et al. | Immunization with the recombinant Burkholderia pseudomallei outer membrane protein Omp85 induces protective immunity in mice | |
| Zhang et al. | Immune protection of rhoptry protein 21 (ROP21) of Toxoplasma gondii as a DNA vaccine against toxoplasmosis | |
| Moreland et al. | Working towards a group A streptococcal vaccine: report of a collaborative Trans-Tasman workshop | |
| HRP20170094T1 (hr) | Imunogeni pripravak | |
| JP2011250797A5 (hr) | ||
| JP2012515551A5 (hr) | ||
| Suzuki et al. | C-terminal Clostridium perfringens enterotoxin-mediated antigen delivery for nasal pneumococcal vaccine | |
| Parma et al. | Antibodies anti-Shiga toxin 2 B subunit from chicken egg yolk: isolation, purification and neutralization efficacy | |
| De Amicis et al. | Analysis of the coverage capacity of the StreptInCor candidate vaccine against Streptococcus pyogenes | |
| RU2015106916A (ru) | Полипептиды clostridium difficile в виде вакцины | |
| MX2018003352A (es) | Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer. | |
| Collado et al. | Probing vaccine antigens against bovine mastitis caused by Streptococcus uberis | |
| RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
| Lu et al. | Protective immune responses elicited by fusion protein containing PsaA and PspA fragments | |
| Vadesilho et al. | Characterization of the antibody response elicited by immunization with pneumococcal surface protein A (PspA) as recombinant protein or DNA vaccine and analysis of protection against an intranasal lethal challenge with Streptococcus pneumoniae | |
| CN106794236A (zh) | A群链球菌疫苗 | |
| RU2011140508A (ru) | Антигены хламидии | |
| JP2015529677A5 (hr) | ||
| Lee et al. | Protection against Vibrio vulnificus infection by active and passive immunization with the C-terminal region of the RtxA1/MARTXVv protein | |
| Kumar et al. | Outer membrane protein assembly factor YaeT (omp85) and GroEL proteins of Edwardsiella tarda are immunogenic antigens for Labeo rohita (Hamilton) | |
| Im et al. | Comparative analysis of immune responses to outer membrane antigens OMP10, OMP19, and OMP28 of Brucella abortus |